These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1102 related items for PubMed ID: 17576867

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT, Dobromirski M.
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [Abstract] [Full Text] [Related]

  • 23. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
    Kakar P, Watson T, Lip GY.
    Curr Opin Investig Drugs; 2007 Mar; 8(3):256-65. PubMed ID: 17408122
    [Abstract] [Full Text] [Related]

  • 24. Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
    Kwong LM.
    Orthopedics; 2012 Jun; 35(6):e932-8;discussion e939. PubMed ID: 22691670
    [Abstract] [Full Text] [Related]

  • 25. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G.
    Clin Appl Thromb Hemost; 2009 Jun; 15(4):389-94. PubMed ID: 19608550
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM.
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [Abstract] [Full Text] [Related]

  • 28. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF, Ganetsky V, Spinler SA.
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [Abstract] [Full Text] [Related]

  • 29. [Summary and perspectives. Rivaroxaban].
    Albaladejo P.
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S28-31. PubMed ID: 19185785
    [Abstract] [Full Text] [Related]

  • 30. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):57-72. PubMed ID: 22272729
    [Abstract] [Full Text] [Related]

  • 31. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.
    Thromb Haemost; 2011 Mar 01; 105(3):444-53. PubMed ID: 21136019
    [Abstract] [Full Text] [Related]

  • 32. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR.
    J Bone Joint Surg Br; 2009 May 01; 91(5):636-44. PubMed ID: 19407299
    [Abstract] [Full Text] [Related]

  • 33. Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
    Komotar RJ, Starke RM, Connolly ES.
    Neurosurgery; 2008 Oct 01; 63(4):N10-1. PubMed ID: 18981864
    [No Abstract] [Full Text] [Related]

  • 34. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E, Araújo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F, CLETRAT Investigators.
    Thromb Res; 2004 Oct 01; 114(3):149-53. PubMed ID: 15342210
    [Abstract] [Full Text] [Related]

  • 35. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.
    J Med Econ; 2014 Oct 01; 17(10):691-5. PubMed ID: 25065536
    [Abstract] [Full Text] [Related]

  • 36. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
    Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P, Cook-Bruns N, Lensing AW, Haskell L, Perzborn E, Kubitza D, Moore KT, Jalota S, Weber J, Pan G, Sun X, Westermeier T, Nadel A, Oppenheimer L, DiBattiste PM.
    Ann N Y Acad Sci; 2013 Jul 01; 1291():42-55. PubMed ID: 23701516
    [Abstract] [Full Text] [Related]

  • 37. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
    Pernod G, Elias A, Gouin I, Gaillard C, Nguyen P, Ouvry P, Sié P.
    J Mal Vasc; 2012 Dec 01; 37(6):300-10. PubMed ID: 23122646
    [Abstract] [Full Text] [Related]

  • 38. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M.
    J Clin Pharmacol; 2006 Sep 01; 46(9):981-90. PubMed ID: 16920892
    [Abstract] [Full Text] [Related]

  • 39. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G.
    Clin Pharmacol Ther; 2005 Oct 01; 78(4):412-21. PubMed ID: 16198660
    [Abstract] [Full Text] [Related]

  • 40. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
    van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW.
    Curr Med Res Opin; 2014 May 01; 30(5):829-37. PubMed ID: 24432872
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.